S-HPABA, a marine fungal-derived bioactive compound, exhibits potent lipid-lowering efficacy and safety in modulating lipid dysregulation revealed by integrative lipidomics and molecular biology approaches

Introduction

Hyperlipidemia is a widespread metabolic disorder that places a heavy burden on normal body functions. Given the drawbacks of current lipid-lowering drugs, there is considerable interest in developing alternative nutraceuticals from natural sources. S-2-(2-hydroxypropanamido) benzoic acid (S-HPABA) is a novel compound obtained for the first time from a marine fungus, which has demonstrated strong lipid-lowering effects in vitro and in vivo with an excellent safety profile.